project id: TCGA-TGCT; case submitter id: TCGA-YU-A94D; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.81; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.39; rna integrity number: 7.9; age at index: 28; days to birth: -10427; ethnicity: not reported; gender: male; race: not reported; vital status: Alive; year of birth: 1981; age at diagnosis: 10427; ajcc clinical m: M1a; ajcc clinical n: N0; ajcc clinical stage: Stage IIIB; ajcc pathologic stage: Stage IIIB; ajcc pathologic t: T3; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 2167.0; icd 10 code: C62.90; igcccg stage: Intermediate Prognosis; last known disease status: not reported; morphology: 9080/3; primary diagnosis: Teratoma, malignant, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Testis, NOS; synchronous malignancy: No; tissue or organ of origin: Testis, NOS; tumor grade: Not Reported; year of diagnosis: 2009; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1746; days to sample procurement: 0; initial weight: 40.0; portion submitter id: TCGA-YU-A94D-01A-11; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 90.0;